Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alignment Healthcare operates a tech-enabled Medicare Advantage platform serving seniors across California, North Carolina, Nevada, Arizona, and Texas. The company differentiates through its proprietary Aveta care coordination platform that integrates clinical data, predictive analytics, and in-home care delivery to manage high-cost chronic conditions. With 48% revenue growth and expanding into new geographies, ALHC is scaling rapidly but remains unprofitable with negative 4.7% net margins as it invests heavily in member acquisition and technology infrastructure.
ALHC receives fixed monthly capitated payments from CMS for each enrolled Medicare Advantage member, with risk-adjusted premiums based on member health status (HCC scores). Profitability depends on managing medical loss ratios below premium levels through proactive care management, utilization controls, and preventing high-cost acute events. The Aveta platform enables predictive risk stratification to identify members likely to require expensive interventions, allowing preventive in-home care that reduces hospital admissions. Competitive advantage stems from proprietary technology that integrates claims, clinical, social determinants data in real-time, plus owned care delivery infrastructure including 24/7 care teams and home-based primary care. Operating leverage improves as fixed technology and administrative costs spread across growing membership base, though current scale insufficient for profitability.
Medicare Advantage membership growth and retention rates (currently growing 40%+ annually)
Medical loss ratio performance versus 85% target threshold and CMS Star Ratings impact on bonus payments
Geographic expansion announcements and new county approvals from CMS for service area expansion
CMS rate notices for annual Medicare Advantage payment updates (typically announced February, effective following January)
Quarterly medical cost trend performance and ability to manage utilization below actuarial assumptions
CMS rate pressure and regulatory changes to Medicare Advantage payment methodology, including ongoing scrutiny of risk adjustment coding practices and potential payment cuts to reduce federal spending
Shift toward value-based care and direct contracting models where health systems bypass MA plans to contract directly with CMS, disintermediating insurers
Technology platform obsolescence risk if competitors develop superior predictive analytics or care coordination tools, eroding differentiation
Intense competition from scaled national players (UnitedHealth, Humana, CVS/Aetna) with 10x+ membership scale, deeper provider relationships, and ability to underprice in key markets
Provider-sponsored health plans (Kaiser, SCAN Health) expanding in California and other core markets with integrated delivery advantages
New entrants including tech companies (Amazon, Walmart Health) leveraging technology and retail footprint to disrupt traditional MA distribution
Negative equity position and ongoing cash burn requiring future capital raises that dilute existing shareholders, particularly if growth disappoints or MLR deteriorates
Medical claims payable volatility and reserve adequacy risk if utilization exceeds actuarial assumptions, requiring reserve strengthening that impacts reported earnings
Regulatory capital requirements and risk-based capital (RBC) ratios that constrain growth if profitability doesn't improve, potentially requiring capital injection
low - Medicare Advantage revenue is government-funded through CMS capitated payments, insulating from economic cycles. Member enrollment driven by demographics (aging population) rather than employment or GDP. However, supplemental benefit utilization and member satisfaction may show modest sensitivity to consumer confidence. Recession could pressure state Medicaid programs if dual-eligible population grows, though this represents upside enrollment opportunity.
Rising rates create moderate headwinds through higher discount rates on unprofitable growth story, compressing valuation multiples typical for high-growth healthcare stocks. Company holds minimal interest-bearing debt (2.04 D/E ratio appears elevated due to negative equity from accumulated losses, not leverage). Investment portfolio of $400M+ in short-term securities benefits from higher yields on cash balances. Rate sensitivity primarily valuation-driven rather than operational, as Medicare premiums unaffected by rate environment.
Minimal direct credit exposure. Revenue from CMS represents zero credit risk. Provider network payments are short-cycle payables. Primary financial risk is liquidity management given negative operating cash flow requiring capital raises to fund growth. Credit market conditions affect ability to access capital markets for equity or debt financing to fund expansion, though current balance sheet appears adequate through 2026-2027 based on cash burn rate.
growth - investors attracted to 48% revenue growth, large TAM in Medicare Advantage (only 50% penetration of eligible seniors), and technology differentiation story. Stock appeals to healthcare growth specialists willing to accept near-term losses for market share gains in structurally growing senior healthcare market. Recent 49% one-year return suggests momentum investors participating. Not suitable for value or income investors given negative profitability and no dividend. Institutional ownership likely concentrated among healthcare-focused growth funds.
high - small-cap healthcare stock with $4.1B market cap exhibits elevated volatility. Beta likely 1.3-1.5x given growth profile and unprofitability. Stock highly sensitive to quarterly earnings surprises on membership or MLR metrics, CMS policy announcements, and broader healthcare regulatory sentiment. Recent 28% three-month gain demonstrates momentum-driven price action. Options market likely prices elevated implied volatility around earnings and CMS rate announcements.
